Orthofix saw net sales of $205.6 million in the third quarter, a 5% increase year over year, according to financial results posted Nov. 4.
Six things to know:
1. Net sales of $205.6 million include revenue from the discontinued M6 artificial disc. Excluding M6, quarterly sales were $203.4 million.
2. U.S. spinal fixation sales increased 8% year over year, and procedure volume grew 10% year over year.
3. Bone growth therapies saw net sales of $61.2 million, a 6% increase year over year.
4. Global orthopedic sales increased 6% year over year with $33.6 million.
5. Orthofix saw a net loss of $22.8 million.
6. Orthofix narrowed its 2025 full-year guidance and expects pro forma net sales to range between $810 million to $814 million.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
